Toxic anterior segment syndrome (TASS) is a surgical complication resulting from a noninfectious inflammatory reaction to substances used during intraocular ophthalmic surgery. Continuous reporting of new information concerning risk factors and possible causes is critical for preventing this condition. The diagnosis of TASS is clinical and its main features are well known. However, new causes of TASS are emerging and being reported, as are new treatment options for managing the inflammation or its complications, and prevention guidelines are being updated. This article presents current and novel information regarding these topics. Educating the medical community regarding potential causes of TASS and its prevention is necessary for improving management of TASS. Thorough investigations and reports of TASS cases are a fundamental step in achieving this goal. Still, as the complete eradication of TASS solely through prevention is unlikely, further studies regarding TASS's pathophysiology, systemic and ocular risk factors, and new treatment options are necessary.
Purpose: To evaluate the effect of a single subconjunctival aflibercept injection on formed corneal neovascularization. Methods: A prospective clinical trial, conducted at a single tertiary medical center. Included were consecutive patients with corneal pathologies complicated by corneal neovascularization, who were candidates for anti–vascular endothelial growth factor treatment at the discretion of a cornea specialist. A single subconjunctival injection of 0.08 mL of Aflibercept (Eylea 25 mg/mL) was administered near the limbus in proximity to the areas of maximal pathological neovascularization. Follow-up visits were scheduled on days 7, 30, 60, and 90 following injection. Best-corrected visual acuity (BCVA), intraocular pressure, slitlamp examination, digital cornea photography, specular microscopy, and anterior-segment optical coherence tomography were documented at each visit. The images were graded by a masked observer for density, extent, and centricity of corneal vascularization. Results: Six eyes of six patients were analyzed. No clinically significant ocular or systemic adverse events were documented. No change was noted in extent, density, or centricity of corneal blood vessels at seven, 30, and 90 days after injection (P>0.1 for all time point comparisons, Friedman test). Best-corrected visual acuity fluctuated insignificantly in 5/6 patients during follow-up time, and objective but not subjective improvement of BCVA was noted in one patient with no concurrent change of neovascularization. The recruitment has therefore halted prematurely. Conclusions: A single subconjunctival aflibercept injection seems to be well tolerated. However, it is ineffective for regressing formed corneal neovascularization.
BACKGROUND AND OBJECTIVE: To evaluate the outcomes of femtosecond laser in situ keratomileusis (LASIK) compared to combined LASIK and astigmatic keratotomy in the treatment of refractive errors following penetrating keratoplasty. PATIENTS AND METHODS: A retrospective review was performed on 18 eyes of 16 patients who underwent LASIK for visual rehabilitation after penetrating keratoplasty. Seven eyes (38.8%) had undergone paired relaxing incisions with topographic guidance prior to LASIK performance. RESULTS: Preoperative uncorrected visual acuity was 20/100 or worse in 13 eyes (72.2%) and best-corrected visual acuity (BCVA) was 20/40 or better in 15 eyes (83.3%). After LASIK, uncorrected visual acuity was 20/40 or better in 10 eyes (55.5%) and BCVA was 20/40 or better in 17 eyes (94.4%). Three eyes (16.6%) had a loss of 1 to 2 lines of BCVA. No difference in visual outcomes was noted in eyes undergoing LASIK and astigmatic keratotomy versus LASIK alone. An increased complication rate was noted in patients who also underwent astigmatic keratotomy and was associated with flap creation. CONCLUSION: Femtosecond LASIK is effective in reducing ametropia after penetrating keratoplasty. Astigmatic keratotomy might complicate flap creation in LASIK; therefore, photorefractive keratectomy should be considered for patients who had previous astigmatic keratotomy to reduce astigmatism. [Ophthalmic Surg Lasers Imaging 2010;41:242–249.]
9 December 2020 in European Journal of Ophthalmology
To compare the outcomes of femtosecond laser assisted in situ keratomileusis (FS-LASIK) with transepithelial photorefractive keratectomy (T-PRK) for the correction of high-grade astigmatism. Medical records of patients with astigmatism of 2 diopters (D) or higher, who were treated with FS-LASIK or T-PRK in 2013 through 2014 at a private practice laser clinic, were retrospectively analyzed. Efficacy, safety, predictability and vector analysis of astigmatism correction were compared between the treatment groups. The study included 93 eyes treated with FS-LASIK and 186 eyes treated with T-PRK. No significant differences in postoperative spherical equivalent (−0.10 ± 0.7 D and −0.11 ± 0.7 D, respectively, p = 0.958) and postoperative refractive astigmatism (0.79 ± 0.54 D and 0.82 ± 0.63 D, respectively, p = 0.685) were demonstrated. A significant advantage of FS-LASIK over T-PRK was seen for the efficacy (1.00 ± 0.18 and 0.86 ± 0.22, respectively, p < 0.001) and safety (1.03 ± 0.17 and 0.89 ± 0.21, respectively, p < 0.001) indices. Results remain statistically significant in a multivariate analysis model. Vector analysis for the astigmatism correction showed no significant difference between the surgery methods in the surgically induced astigmatism, difference vector, correction index and index of success. Both procedures demonstrated desirable post-operative SE outcomes for high-grade astigmatism correction. However, FS-LASIK achieved better results than T-PRK in the efficacy and safety parameters.